Introduction
HTATIP2, a member of the short-chain dehydrogenases/reductases (SDR) family, functions as a tumor suppressor. It achieves this by suppressing metabolism, inhibiting angiogenesis, and inducing the expression of apoptosis-related genes Bad and Siva. HTATIP2 interacts with the activation domain of HIV-1 TAT, enhancing its transcription through phosphorylation of RNA polymerase II (Pol II). Defects in HTATIP2 are linked to hepatocellular carcinomas and apoptotic-resistant tumor cells, suggesting its potential in antitumor therapy.
Physical Appearance
A clear, colorless solution that has been sterilized by filtration.
Formulation
The solution contains 1mg/ml of HTATIP2 antibody in a buffer consisting of PBS at pH 7.4, 10% glycerol, and 0.02% sodium azide.
Storage Procedures
For short-term storage (up to 1 month), keep at 4°C. For longer storage periods, store at -20°C. Avoid repeated freeze-thaw cycles.
Stability / Shelf Life
The product is stable for 12 months when stored at -20°C and for 1 month at 4°C.
Applications
This HTATIP2 antibody has been validated for use in ELISA, Western blot analysis, Flow cytometry, and ICC/IF to ensure its specificity and reactivity. However, optimal working dilutions should be determined empirically for each application.
Synonyms
TIP30, CC3, SDR44U1, HTATIP2, EC=1.1.1.-, HIV-1 TAT-interactive protein 2, FLJ26963.
Purification Method
HTATIP2 antibody was purified from mouse ascitic fluids by protein-A affinity chromatography.
Type
Mouse Anti Human Monoclonal.
Immunogen
Anti-human HTATIP2 mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human HTATIP2 amino acids 1-242 purified from E. coli.
Ig Subclass
Mouse IgG2a heavy chain and ? light chain.